Nanobiotix SA

5NR

Company Profile

  • Business description

    Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

  • Contact

    60 Rue de Wattignies
    Paris75012
    FRA

    T: +33 140260470

    https://www.nanobiotix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    97

Stocks News & Analysis

stocks

Strong guidance from undervalued ASX share

Shares surged after the announcement of first half fiscal 2026 guidance.
stocks

TSMC earnings: Refining guidance and expansion plans amid strong AI demand

We maintain our fair value estimate for TSMC stock.
stocks

Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio

Trying to make sense of a share caught up in irrational exuberance.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,168.7033.000.36%
CAC 408,425.130.000.00%
DAX 4024,702.24547.772.27%
Dow JONES (US)49,447.43868.711.79%
FTSE 10010,667.6377.640.73%
HKSE26,160.33233.93-0.89%
NASDAQ24,468.48365.781.52%
Nikkei 22558,475.901,042.44-1.75%
NZX 50 Index12,905.67160.39-1.23%
S&P 5007,126.0684.781.20%
S&P/ASX 2008,946.9036.800.41%
SSE Composite Index4,051.434.12-0.10%

Market Movers